PL352403A1 - Substituted polycyclic aryl and heteroaryl pyridones useful for selective inhibition of coagulation cascade - Google Patents

Substituted polycyclic aryl and heteroaryl pyridones useful for selective inhibition of coagulation cascade

Info

Publication number
PL352403A1
PL352403A1 PL00352403A PL35240300A PL352403A1 PL 352403 A1 PL352403 A1 PL 352403A1 PL 00352403 A PL00352403 A PL 00352403A PL 35240300 A PL35240300 A PL 35240300A PL 352403 A1 PL352403 A1 PL 352403A1
Authority
PL
Poland
Prior art keywords
coagulation cascade
selective inhibition
polycyclic aryl
substituted polycyclic
heteroaryl
Prior art date
Application number
PL00352403A
Other languages
English (en)
Inventor
Michael S South
Qingpeng Zeng
Melvin L Rueppel
Original Assignee
Pharmacia Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Corp filed Critical Pharmacia Corp
Publication of PL352403A1 publication Critical patent/PL352403A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/76—Nitrogen atoms to which a second hetero atom is attached
    • C07D213/77—Hydrazine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Quinoline Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PL00352403A 1999-05-19 2000-05-15 Substituted polycyclic aryl and heteroaryl pyridones useful for selective inhibition of coagulation cascade PL352403A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13481199P 1999-05-19 1999-05-19
PCT/US2000/008220 WO2000069826A1 (fr) 1999-05-19 2000-05-15 Pyridones aryle et heteroaryle polycycliques substituees utilisees pour l'inhibition selective de la cascade de coagulation

Publications (1)

Publication Number Publication Date
PL352403A1 true PL352403A1 (en) 2003-08-25

Family

ID=22465131

Family Applications (1)

Application Number Title Priority Date Filing Date
PL00352403A PL352403A1 (en) 1999-05-19 2000-05-15 Substituted polycyclic aryl and heteroaryl pyridones useful for selective inhibition of coagulation cascade

Country Status (21)

Country Link
EP (1) EP1178964A1 (fr)
JP (1) JP2002544260A (fr)
KR (1) KR20010113970A (fr)
CN (1) CN1378534A (fr)
AR (1) AR029635A1 (fr)
AU (1) AU771928B2 (fr)
BR (1) BR0011272A (fr)
CA (1) CA2373509A1 (fr)
CZ (1) CZ20014117A3 (fr)
EA (1) EA005367B1 (fr)
HU (1) HUP0201996A3 (fr)
IL (1) IL146244A0 (fr)
MX (1) MXPA01011805A (fr)
MY (1) MY138303A (fr)
NO (1) NO20015606L (fr)
NZ (1) NZ514875A (fr)
PL (1) PL352403A1 (fr)
SK (1) SK15862001A3 (fr)
UY (1) UY26154A1 (fr)
WO (1) WO2000069826A1 (fr)
ZA (2) ZA200109340B (fr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6458952B1 (en) 1999-05-19 2002-10-01 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl uracils useful for selective inhibition of the coagulation cascade
US6750342B1 (en) 1999-05-19 2004-06-15 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl pyrimidinones useful for selective inhibition of the coagulation cascade
US6664255B1 (en) 1999-05-19 2003-12-16 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl pyrazinones useful for selective inhibition of the coagulation cascade
US6867217B1 (en) 1999-05-19 2005-03-15 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl pyridones useful for selective inhibition of the coagulation cascade
US6653316B1 (en) 1999-05-19 2003-11-25 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl pyrimidinones useful for selective inhibition of the coagulation cascade
US7015230B1 (en) 1999-05-19 2006-03-21 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl uracils useful for selective inhibition of the coagulation cascade
US6716838B1 (en) 1999-05-19 2004-04-06 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl uracils as anticoagulative agents
US6660885B2 (en) 2000-03-13 2003-12-09 Pharmacia Corporation Polycyclic aryl and heteroaryl substituted benzenes useful for selective inhibition of the coagulation cascade
DE60108948T2 (de) 2000-04-05 2005-11-03 Pharmacia Corp. Polyzyclisch aryl und heteroaryl substituierte 4-pyronen verwendbar als selektive hemmung von dem koagulationsprozess
EP1268428A2 (fr) 2000-04-05 2003-01-02 Pharmacia Corporation Pyridones polycycliques 4-aryl et heteroaryl substituees utiles pour l'inhibition selective de la cascade de coagulation
WO2001079195A2 (fr) * 2000-04-14 2001-10-25 Corvas International, Inc. Nouveaux inhibiteurs de thrombine de type non covalent
CA2405684A1 (fr) 2000-04-17 2001-10-25 Pharmacia Corporation 1,4-quinones polycycliques substituees par aryle et heteroaryles utiles pour l'inhibition selective des reactions en cascade provoquant la coagulation
AU2001217827A1 (en) * 2000-05-18 2001-11-26 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl pyridones useful for selective inhibition of the coagulation cascade
US6710058B2 (en) 2000-11-06 2004-03-23 Bristol-Myers Squibb Pharma Company Monocyclic or bicyclic carbocycles and heterocycles as factor Xa inhibitors
US7119094B1 (en) 2000-11-20 2006-10-10 Warner-Lambert Company Substituted polycyclic aryl and heteroarpyl pyrazinones useful for selective inhibition of the coagulation cascade
JP2004517074A (ja) 2000-11-20 2004-06-10 ファルマシア・コーポレーション 凝血カスケードを選択的に阻害するのに有用な置換された多環アリールおよびヘテロアリールピリジン類
US7015223B1 (en) 2000-11-20 2006-03-21 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl 1,2,4-triazinones useful for selective inhibition of the coagulation cascade
ES2330719T3 (es) 2000-12-28 2009-12-15 SHIONOGI & CO., LTD. Derivados de 2-piridona con afinidad para el receptor cannabinoide de tipo 2.
EP1432687A2 (fr) 2001-10-03 2004-06-30 Pharmacia Corporation Composes polycycliques a 5 elements substitues pour l'inhibition selective de la cascade de reactions dans la coagulation sanguine
EP1438292A1 (fr) 2001-10-03 2004-07-21 Pharmacia Corporation Composes heterocycliques a 6 chainons utiles dans l'inhibition selective de la cascade de la coagulation
WO2003048127A1 (fr) * 2001-12-04 2003-06-12 Corvas International, Inc. Inhibiteurs non covalents heterocycliques aromatiques de l'urokinase et de la formation de vaisseaux sanguins
TW200307667A (en) 2002-05-06 2003-12-16 Bristol Myers Squibb Co Sulfonylaminovalerolactams and derivatives thereof as factor Xa inhibitors
US8846935B2 (en) 2010-05-07 2014-09-30 Glaxosmithkline Llc Indazoles
TWI633089B (zh) * 2013-03-28 2018-08-21 拜耳製藥股份有限公司 經取代的酮基吡啶衍生物

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU703744B2 (en) * 1995-06-27 1999-04-01 Merck & Co., Inc. Pyridinone-thrombin inhibitors
WO1997030708A1 (fr) * 1996-02-22 1997-08-28 Merck & Co., Inc. Inhibiteurs de pyridinone thrombine
WO1999011267A1 (fr) * 1997-09-05 1999-03-11 Merck & Co., Inc. Inhibiteurs de thrombine a base de pyrazinone
JP2001502674A (ja) * 1996-10-11 2001-02-27 シーオーアール・セラピューティックス・インコーポレーテッド 選択的Ｘａ因子阻害物質
US5792779A (en) * 1997-02-19 1998-08-11 Merck & Co., Inc. Pyridinone thrombin inhibitors
JP2001518932A (ja) * 1997-03-24 2001-10-16 メルク エンド カンパニー インコーポレーテッド トロンビン阻害薬
IL123986A (en) * 1997-04-24 2011-10-31 Organon Nv Medicinal compounds
ATE306261T1 (de) * 1997-06-26 2005-10-15 Lilly Co Eli Antithrombosemittel
CA2311969A1 (fr) * 1997-11-26 1999-06-03 3-Dimensional Pharmaceuticals, Inc. Heteroaryl aminoguanidines et alcoxyguanidines et leur utilisation en tant qu'inhibiteurs de protease
CA2343109A1 (fr) * 1998-09-28 2000-04-06 Merck & Co., Inc. Inhibiteurs de la thrombine
EP1124822A4 (fr) * 1998-10-30 2002-04-03 Merck & Co Inc Inhibiteurs de la thrombine
JP2002528542A (ja) * 1998-10-30 2002-09-03 メルク エンド カムパニー インコーポレーテッド トロンビン阻害剤
FR2786482B1 (fr) * 1998-11-27 2002-08-09 Synthelabo Nouveaux derives de 2-pyridone, leur preparation et leur application en therapeutique

Also Published As

Publication number Publication date
CN1378534A (zh) 2002-11-06
ZA200109340B (en) 2004-05-26
HUP0201996A3 (en) 2002-12-28
JP2002544260A (ja) 2002-12-24
NZ514875A (en) 2004-10-29
SK15862001A3 (sk) 2002-08-06
AR029635A1 (es) 2003-07-10
HUP0201996A2 (en) 2002-09-28
ZA200400449B (en) 2004-11-24
MY138303A (en) 2009-05-29
NO20015606L (no) 2002-01-21
MXPA01011805A (es) 2003-09-04
AU771928B2 (en) 2004-04-08
CZ20014117A3 (cs) 2002-05-15
BR0011272A (pt) 2002-05-07
EP1178964A1 (fr) 2002-02-13
KR20010113970A (ko) 2001-12-28
IL146244A0 (en) 2002-07-25
EA200101213A1 (ru) 2002-04-25
UY26154A1 (es) 2000-12-29
WO2000069826A1 (fr) 2000-11-23
AU4797300A (en) 2000-12-05
NO20015606D0 (no) 2001-11-16
EA005367B1 (ru) 2005-02-24
CA2373509A1 (fr) 2000-11-23

Similar Documents

Publication Publication Date Title
PL352403A1 (en) Substituted polycyclic aryl and heteroaryl pyridones useful for selective inhibition of coagulation cascade
GB2357390B (en) Ethernet units adapted for loop configuration and method of operating same
AU4677399A (en) Inhibitors of H+K+-ATPase
PL366334A1 (en) Pyridinone derivatives for treatment of atherosclerosis
IL146245A0 (en) Substituted polycyclic aryl and heteroaryl pyrazinones useful for selective inhibition of the coagulation cascade
NO20015547L (no) Fremgangsmåte for hemisyntese av forbindelser og nye forbindelser
AU6041599A (en) Time-based disablement of equipment
HUP0101407A3 (en) Process for synthesizing pyridine derivatives as cox-2 inhibitors and the intermediates
AU5056300A (en) Devices and compounds for treating arterial restenosis
AU2001243598A1 (en) Polycyclic aryl and heteroaryl substituted benzenes useful for selective inhibition of the coagulation cascade
NO20012963D0 (no) Fremgangsmåte for fremstilling av 3-alkanoylindoler og 3- alkylindoler
AU1488501A (en) Methods of inhibiting metastasis
AU1036601A (en) Method of screening for inhibitors of asp1
AU2002220735A1 (en) Substituted derivatives of aminofuran-2-yl-acetic acid and aminothien-2-yl-acetic acid and the use thereof for treating migraines and pain
AU2001219236A1 (en) Substituted polycyclic aryl and heteroaryl uracils useful for selective inhibition of the coagulation cascade
AU2001217827A1 (en) Substituted polycyclic aryl and heteroaryl pyridones useful for selective inhibition of the coagulation cascade
AU2547401A (en) Interference signal eliminating apparatus and method of eliminating interferencesignal
EP1221963A4 (fr) Methodes d'inhibition de l'osteoclastogenese
AU2001222501A1 (en) Substituted polycyclic aryl and heteroaryl pyrimidinones useful for selective inhibition of the coagulation cascade
AU4021700A (en) Methods of use of beta1-integrin inhibitors
AU2002213878A1 (en) Use of erythropoietin and the derivatives of the same for treating schizophrenia and related psychoses
GB9926421D0 (en) Process for selective mono-debromination of polybromoalkyl aryl or heteroaryl ketones
AU1784701A (en) Method of treating neuroblastoma
AU2499900A (en) Attachable freshener and method of using same
PL336613A1 (en) Cabinet for safe-keeping property and method of making such cabinet

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)